Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on July 12, 2005. The filing discloses the election of a new director to the Board of Directors and the associated equity compensation awards granted in connection with this appointment.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The financial data presented is limited to the terms of specific equity awards:
- Stock Options: 75,000 shares at an exercise price of $7.02 per share.
- Restricted Stock: 10,000 shares purchased at $7.02 per share.
Material Changes
The primary material change reported is the expansion of the Board of Directors. James L. Vincent was elected to fill a vacancy and will serve as a Class II director with a term expiring at the 2006 annual meeting of stockholders.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, financial outlook, or general management commentary regarding business operations. It strictly details the terms of the compensation agreements attached as exhibits (Exhibit 10.1 and 10.2). The vesting schedule for the options is one-third annually over three years, contingent on continued service. The restricted stock vests one week post-election, also contingent on continued service.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2004 Stock Incentive Plan to assess the impact of these new grants.
- Confirm the current market price of Alnylam common stock relative to the $7.02 exercise/purchase price to determine if the awards are in-the-money.
- Review the full text of the Nonstatutory Stock Option Agreement (Exhibit 10.1) and Restricted Stock Agreement (Exhibit 10.2) for specific forfeiture or acceleration clauses.
- Check subsequent filings to confirm Mr. Vincent's continued service and the vesting of the awards.